The incidence of prostate cancer in hypogonadal men receiving testosterone replacement therapy is the subject of this article. Observations from three registries’ 5-year median follow-up. What exactly does this mean? So we’re talking about men who have low T, which is something of a buzzword in the medical community. We call it hypogonadal, which means that the gonads are simply not functioning properly, but is testosterone replacement therapy and what is the risk of these men who do not have prostate cancer or what is the risk of these men developing prostate cancer, and the median follow-up is actually five years. This is an extremely important study.
This was done in Europe, and there were numerous studies on purchasing Hydrodol. There were several from Germany and the UAE, so there was a lot of this multi-institutional paper that looked at the number of these studies. So, what did they discover? The first thing I’ll say as a spoiler is that they didn’t find an increase in the risk of developing prostate cancer in men on testosterone replacement therapy. Let me say that again, because there are many myths and folklore out there that claim that taking testosterone replacement therapy will increase your risk of prostate cancer. First and foremost, I am certain that putting a man on testosterone replacement therapy will increase his risk. This study discovered that you can reduce your risk by about 1000 men.
We’ll get to that in a moment, but what we do know, at least in this paper, I can’t say is the word of God, but I can tell you that it’s a very good paper that looks at these men over time. The median follow-up was about five years, but there was no increased risk of these men being diagnosed with prostate cancer with a five-year follow-up. They took these men who had hypogonadism and implanted them and were basically guys who were, you know, 60 and up. They just wanted to get back into the gym and compete in a new bench press competition.
These men had a legitimate problem and symptoms consistent with hypogonadism, so they started them on testosterone replacement therapy and closely monitored their PSA. So, rather than going into the entire design of the study, I’m not going to cut to the chase and tell you what the findings were. So, what does that mean? Well, if you look at some of the previous studies, as well as some of the screening studies, they actually look at the risk of developing prostate cancer.It’s upwards of about 79%. Okay, give it a take that same time period, so can I tell you that you are actually inhibiting your risk of prostate cancer? I can’t tell you that.
This paper is very well designed. However, it is important that if a man decides to undergo testosterone replacement therapy, we follow him closely. We have a number of men in my clinic and in my partners’ clinics where we have put them on testosterone replacement therapy. If we start seeing that PSA rise at a higher rate than we’d like to see, we treat them just like guys who are already on testosterone replacement therapy. We talk to them about the potential need for a biopsy or try to figure out if there could be a focal point of cancer, but we look at that and look at each man individually, whether they’re on testosterone or not.
The takeaway from that is that we have a paper and I say a very well designed paper that looks at men with an average age of about five years to follow up on this that shows there is no increased risk of prostate cancer if you’re on testosterone replacement therapy. I think we’ll start to see more and more of these studies emerge over time, and I think we really need to start looking at the data in terms of people at risk of prostate cancer, and we also of course, we have to be very careful about who we need to Really choose it and who should we put testosterone replacement therapy in general.